Skip to main content
Prolonged survival in patients >= 60 years with first relapsed/refractory acute myeloid leukemia treated with vosaroxin plus cytarabine vs placebo plus cytarabine: Results from the phase 3 VALOR study
Published Web Location
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822512/No data is associated with this publication.